Group 1 - The Rosen Law Firm is reminding purchasers of Elanco Animal Health securities about a class action lawsuit with a lead plaintiff deadline of December 6, 2024 [1][3] - Investors who purchased Elanco securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][3] - The lawsuit alleges that Elanco made false and misleading statements regarding the safety and approval timelines of its products, Zenrelia and Credelio Quattro, which led to overstated business prospects [5] Group 2 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Nov. 22, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN).Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=112959&from=4C ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elanco Animal Health Incorporated due to allegations of misleading statements regarding product safety and approval timelines, which have led to significant investor losses [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in Elanco between November 7, 2023, and June 26, 2024, to discuss their legal options [1]. - A federal securities class action has been filed against Elanco, with a deadline of December 6, 2024, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Elanco and its executives violated federal securities laws by making false statements about the safety of Zenrelia and the timelines for FDA approval of Zenrelia and Credelio Quattro [4]. Group 2: Product Safety and Approval Issues - Elanco's press release on June 27, 2024, indicated that Zenrelia would likely include a boxed warning on safety, which could slow product adoption and limit treatment days by approximately 25% [5]. - The company now expects FDA approval for Zenrelia in Q3 2024 and a commercial launch in Q4 2024, while Credelio Quattro is anticipated to receive FDA approval in Q4 2024 [5]. Group 3: Market Reaction - Following the announcement regarding the safety concerns and revised timelines, Elanco's stock price fell by $3.70 per share, or 20.59%, closing at $14.27 per share on June 27, 2024 [6].

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) --  Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

Core Viewpoint - A lawsuit has been filed against Elanco Animal Health on behalf of investors who purchased its securities during the specified class period, indicating potential legal challenges for the company [1][3]. Company Overview - Elanco Animal Health develops products for both pets and farm animals, including Zenrelia, an oral Janus kinase inhibitor for canine dermatology, and Credelio Quattro, a parasiticide for dogs [3]. FDA Approval Timeline - In November 2023, Elanco set a timeline for U.S. FDA approval of Zenrelia and Credelio Quattro in the first half of 2024 [4]. - By May 2024, Elanco updated its timeline, expecting Zenrelia's approval and commercial launch in Q3 2024, and Credelio Quattro's approval in Q4 2024 [4]. - On June 27, 2024, Elanco indicated that Zenrelia would likely include a boxed safety warning, which could slow product adoption by approximately 25% and delay its approval to Q3 2024, with a potential commercial launch in Q4 2024 [5]. Stock Price Impact - Following the announcement regarding the FDA approval timelines and safety warnings, Elanco's stock price fell by $3.69 per share, or 20%, closing at $14.28 per share on June 27, 2024 [6].

Core Viewpoint - A lawsuit has been filed against Elanco Animal Health Incorporated and certain senior executives for potential violations of federal securities laws, particularly concerning the FDA approval of key drug treatments [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court of Maryland, captioned Barpar v. Elanco Animal Health Incorporated, et al., No. 24-cv-02912 [2]. - Investors have until December 6, 2024, to request to be appointed to lead the case [2]. Group 2: Product Development and FDA Review - Elanco is developing two significant treatments: Zenrelia for dermatitis in dogs and Credelio Quattro, an oral parasiticide for fleas, ticks, and internal parasites [3]. - The company previously stated that the FDA had all necessary data for review and expected approvals by the end of June 2024 [4]. Group 3: Stock Price Impact - Following the announcement that the FDA would not approve the drugs as expected, Elanco's stock price fell over 21%, from $17.97 on June 26, 2024, to $14.27 on June 27, 2024 [5]. - The lawsuit investigates whether Elanco and its executives made materially false or misleading statements regarding the FDA's approval process [5]. Group 4: Legal Representation - Investors in Elanco may have legal options and are encouraged to submit their information to the law firm handling the case, with representation on a contingency fee basis [6]. - The firm has a strong track record in securities class actions, having recovered significant amounts from other companies [7].

NEW YORK, Nov. 18, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN).Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=112073&from=4C ...

NEW YORK, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

Acquisition Details - Elanco Animal Health acquired a contract manufacturing facility and related assets in Speke, UK, previously owned by TriRx Speke Ltd, which was under trading administration [1] - The acquisition cost $25 million in cash at closing, with the company providing interim funding during the administration process [2] - The Speke facility is critical for producing farm animal product lines, generating approximately $160 million to $180 million in annual farm animal revenue, primarily outside the US [2] Strategic Importance - The Speke facility plays a vital role in Elanco's global supply chain for key farm animal products, securing production continuity [2] - Elanco previously held a long-term supply agreement with TriRx Speke Ltd, and the acquisition ensures control over this critical component of its supply chain [2] Financial Impact - Elanco expects an adjusted EBITDA headwind of $25 million to $35 million in 2025 due to the acquisition, primarily impacting gross profit [3] - The company will assume site ownership immediately and work closely with site leadership to support operations [3] Company Overview - Elanco Animal Health is a global leader in animal health, with nearly 70 years of heritage, focusing on innovating and delivering products and services for farm animals and pets [4] - The company is committed to improving animal health and making a meaningful impact on local and global communities, driven by its vision of "Food and Companionship Enriching Life" [4]